doxazosin has been researched along with Hyperlipemia in 9 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We determined the effect of alpha-adrenergic blocking agent doxazosin on insulin resistance in 19 hypertensive patients (blood pressure [BP] >160/90 mmHg) with obesity (mean body mass index [BMI]: 26." | 9.10 | Effect of doxazosin on insulin resistance in hypertensive patients with obesity. ( Miyachi, Y; Ueshiba, H, 2003) |
| "The aim of the study was to investigate the effect of a new selective alpha 1-adrenoreceptor blocker doxazosin on blood pressure, serum lipids and lipoproteins in patients with essential hypertension." | 7.68 | [Doxazosin (alpha 1-adrenoreceptor antagonist) used in primary hypertension and it's beneficial effect on lipid metabolism]. ( Chotkowska, E; Cybulska, I; Galewicz, A; Janaszek-Sitkowska, H; Peczkowska, M; Sawicki, M; Sznajderman, M; Wiernikowska-Wegorek, I, 1993) |
| "We determined the effect of alpha-adrenergic blocking agent doxazosin on insulin resistance in 19 hypertensive patients (blood pressure [BP] >160/90 mmHg) with obesity (mean body mass index [BMI]: 26." | 5.10 | Effect of doxazosin on insulin resistance in hypertensive patients with obesity. ( Miyachi, Y; Ueshiba, H, 2003) |
| " In this article, doxazosin is reviewed for its efficacy in the treatment of severe essential hypertension and specific complications or conditions of mild or moderate essential hypertension, namely, left ventricular hypertrophy, hyperlipidemia, noninsulin-dependent diabetes mellitus, renal insufficiency, pheochromocytoma, chronic obstructive pulmonary disease, peripheral vascular disease, and smoking." | 4.78 | Efficacy of doxazosin in specific hypertensive patient groups. ( Taylor, SH, 1991) |
| "The aim of the study was to investigate the effect of a new selective alpha 1-adrenoreceptor blocker doxazosin on blood pressure, serum lipids and lipoproteins in patients with essential hypertension." | 3.68 | [Doxazosin (alpha 1-adrenoreceptor antagonist) used in primary hypertension and it's beneficial effect on lipid metabolism]. ( Chotkowska, E; Cybulska, I; Galewicz, A; Janaszek-Sitkowska, H; Peczkowska, M; Sawicki, M; Sznajderman, M; Wiernikowska-Wegorek, I, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dhruva, SS | 1 |
| Huang, C | 1 |
| Spatz, ES | 1 |
| Coppi, AC | 1 |
| Warner, F | 1 |
| Li, SX | 1 |
| Lin, H | 1 |
| Xu, X | 1 |
| Furberg, CD | 1 |
| Davis, BR | 1 |
| Pressel, SL | 1 |
| Coifman, RR | 1 |
| Krumholz, HM | 1 |
| Cao, XB | 1 |
| Yang, M | 1 |
| Wang, RY | 1 |
| Ren, LM | 1 |
| Diener, HC | 1 |
| Ueshiba, H | 1 |
| Miyachi, Y | 1 |
| Cheng, TO | 1 |
| Sznajderman, M | 1 |
| Chotkowska, E | 1 |
| Peczkowska, M | 1 |
| Sawicki, M | 1 |
| Janaszek-Sitkowska, H | 1 |
| Wiernikowska-Wegorek, I | 1 |
| Galewicz, A | 1 |
| Cybulska, I | 1 |
| Andersen, P | 1 |
| Seljeflot, I | 1 |
| Herzog, A | 1 |
| Arnesen, H | 1 |
| Hjermann, I | 1 |
| Holme, I | 1 |
| Kowala, MC | 1 |
| Nunnari, JJ | 1 |
| Durham, SK | 1 |
| Nicolosi, RJ | 1 |
| Taylor, SH | 1 |
1 review available for doxazosin and Hyperlipemia
| Article | Year |
|---|---|
Efficacy of doxazosin in specific hypertensive patient groups.
Topics: Adrenal Gland Neoplasms; Antihypertensive Agents; Cardiomegaly; Diabetes Mellitus, Type 2; Doxazosin | 1991 |
3 trials available for doxazosin and Hyperlipemia
| Article | Year |
|---|---|
Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Topics: Aged; Amlodipine; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Cardiovascular Dise | 2017 |
Effect of doxazosin on insulin resistance in hypertensive patients with obesity.
Topics: Adipose Tissue; Adrenergic alpha-Antagonists; Adult; Analysis of Variance; Doxazosin; Female; Humans | 2003 |
Effects of doxazosin and atenolol on atherothrombogenic risk profile in hypertensive middle-aged men.
Topics: Adult; Antihypertensive Agents; Atenolol; Cholesterol, HDL; Doxazosin; Female; Fibrinolysis; Gonadal | 1998 |
5 other studies available for doxazosin and Hyperlipemia
| Article | Year |
|---|---|
[Effects of doxazosin and its enantiomers on serum lipid levels in rabbits fed by an atherogenic diet].
Topics: Animals; Cholesterol, Dietary; Diet, Atherogenic; Doxazosin; Hyperlipidemias; Lipids; Male; Rabbits; | 2010 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic | 2003 |
Should patients with benign prostatic hypertrophy stop taking doxazosin in the light of the ALLHAT study?
Topics: Adrenergic alpha-Antagonists; Anticholesteremic Agents; Antihypertensive Agents; Clinical Trials as | 2006 |
[Doxazosin (alpha 1-adrenoreceptor antagonist) used in primary hypertension and it's beneficial effect on lipid metabolism].
Topics: Adult; Aged; Doxazosin; Female; Humans; Hyperlipidemias; Hypertension; Lipids; Male; Middle Aged | 1993 |
Doxazosin and cholestyramine similarly decrease fatty streak formation in the aortic arch of hyperlipidemic hamsters.
Topics: Adrenergic alpha-Antagonists; Animals; Aorta, Thoracic; Arteriosclerosis; Blood Pressure; Cholestero | 1991 |